SOURCE: Cannabis Science, Inc.

Cannabis Science, Inc.

January 14, 2016 13:12 ET

Cannabis Science California Product Expansion Plans on Heels of Positive Consumer Feedback & Test Marketing of Its Initial Cannabis-Based Products

The Company Excited Using Real Consumer Data to Further Its Critical Drug Development; Cannabis Science Encourages Consumers Across the Nation to Join the Patient Access Center ("PAC")

COLORADO SPRINGS, CO--(Marketwired - Jan 14, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, has received excellent feedback on its initial launch of its capsule products for sale in the California dispensary market.

"Our initial California test market has consumers giving us some amazing feedback to be combined with our proprietary information. We understand the value in using as much real consumer evidence in our drug development programs as possible. There are literally hundreds of dispensaries in the California market. We are ramping up our product offerings and now looking to expand on a very large scale. Following a bit more fine-tuning and test marketing, we will be launching our capsules and some other new products on a full-scale release across California; we are very excited and very motivated. The positive response has made Cannabis Science management optimistic about our national rollout in the near future," said President, CEO, & Co-Founder, Raymond C. Dabney.

Cannabis Science encourages everyone across the nation to join the Patient Access Center ("PAC") on the CBRF website http://cannabisscienceresearchfoundation.org/pac/

Please share your story and learn from the experience of other patients, sign up for your "PAC." The benefits of using cannabis and cannabinoid-based therapies are still a largely unexplored field among healthcare professionals and among many patients. Your input could help mold the cannabinoid medicinal marketplace.

Cannabis Science has found Los Angeles-based Higher Path dispensary to be an initial Flagship Dispensary. Customers have offered great feedback, and the initial test marketing efforts have proven to be a success. Information gathered from initial consumers is being used to fine-tune the short & long-term drug development programs targeting many critical ailments. Higher Path currently showcases many variations available of the CBIS targeted capsules:

https://weedmaps.com/dispensaries/the-higher-path-sherman-oaks#/menu/cannabis-science-whole-plant-extract

https://weedmaps.com/dispensaries/the-higher-path-sherman-oaks#/menu/cannabis-science-thc-capsules-100mg-vegan

https://weedmaps.com/dispensaries/the-higher-path-sherman-oaks#/menu/cannabis-science-cbd-thc-1-1-capsules-50mg-vegan

https://weedmaps.com/dispensaries/the-higher-path-sherman-oaks#/menu/cannabis-science-cbd-thc-1-1-capsules-100mg-vegan

https://weedmaps.com/dispensaries/the-higher-path-sherman-oaks#/menu/cannabis-science-thc-capsules-50mg-vegan

https://weedmaps.com/dispensaries/the-higher-path-sherman-oaks#/menu/cannabis-science-cbd-thc-1-1-capsules-25mg-vegan

https://weedmaps.com/dispensaries/the-higher-path-sherman-oaks#/menu/cannabis-science-thc-capsules-25mg-vegan

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information